HENDERSON MICHAEL THOMAS 4

What Happened
Michael Thomas Henderson, a director of Spyre Therapeutics (SYRE), acquired 63,227 shares on 2026-01-21. The transaction is reported as an "Other acquisition or disposition (J)" at $0.00 per share (total consideration $0). According to the filing footnote, these shares were a pro‑rata distribution of common stock from a limited liability company in which Henderson is a member — a distribution for no consideration rather than an open‑market purchase.

Key Details

• Transaction date: 2026-01-21; Form 4 filed 2026-01-23.
• Transaction code: J (Other acquisition or disposition).
• Shares acquired: 63,227 at $0.00 each; aggregate value reported $0.
• Footnote: Pro‑rata distribution of shares for no consideration from an LLC (the Reporting Person is a member).
• Shares owned after transaction: Not stated in the provided filing.
• Filing timeliness: Form filed two days after the transaction date; no late filing indicated in the provided data.

Context
This was a distribution of shares from an LLC, not a market purchase or sale; such distributions are typically administrative/ownership‑structure events and do not necessarily indicate the director’s view on the company’s stock. Retail investors should treat distributions and gifts differently from purchases or sales when interpreting insider activity.